+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

High-density Multiplexed Diagnostic Assays - Global Market Trajectory & Analytics

  • ID: 5139838
  • Report
  • April 2021
  • Region: Global
  • 175 Pages
  • Global Industry Analysts, Inc
Global High-density Multiplexed Diagnostic Assays Market to Reach $3.2 Billion by 2027

Amid the COVID-19 crisis, the global market for High-density Multiplexed Diagnostic Assays estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 14.4% over the period 2020-2027. High-Density Multiplexed Diagnostic Assays (500-10,000 plex), one of the segments analyzed in the report, is projected to record 14.1% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) segment is readjusted to a revised 14.9% CAGR for the next 7-year period.



The U.S. Market is Estimated at $363.6 Million, While China is Forecast to Grow at 13.9% CAGR

The High-density Multiplexed Diagnostic Assays market in the U.S. is estimated at US$363.6 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$551.1 Million by the year 2027 trailing a CAGR of 13.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 12.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Select Competitors (Total 46 Featured):
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Erba Diagnostics, Inc.
  • F. Hoffmann-La Roche AG
  • Gold Standard Diagnostics Corporation
  • Hologic, Inc.
  • Luminex Corporation
  • Randox Laboratories Ltd.
  • Thermo Fisher Scientific, Inc.
Frequently Asked Questions about the Global Market for High-density Multiplexed Diagnostic Assays

What is the estimated value of the Global Market for High-density Multiplexed Diagnostic Assays?

The Global Market for High-density Multiplexed Diagnostic Assays was estimated to be valued at $1.2 Billion in 2020.

What is the growth rate of the Global Market for High-density Multiplexed Diagnostic Assays?

The growth rate of the Global Market for High-density Multiplexed Diagnostic Assays is 15.0%, with an estimated value of $3.2 Billion by 2027.

What is the forecasted size of the Global Market for High-density Multiplexed Diagnostic Assays?

The Global Market for High-density Multiplexed Diagnostic Assays is estimated to be worth $3.2 Billion by 2027.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for High-density Multiplexed Diagnostic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Clinical Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Clinical Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Hospitals and Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Hospitals and Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Hospitals and Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS
  • Table 16: USA Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 17: USA Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: USA 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 19: USA Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: USA Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: USA 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 22: Canada Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 23: Canada Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: Canada 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 25: Canada Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: Canada 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 28: Japan Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: Japan Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: Japan 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 31: Japan Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Japan Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Japan 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 34: China Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: China Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: China 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 37: China Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: China Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: China 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 40: Europe Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 41: Europe Historic Review for High-density Multiplexed Diagnostic Assays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Europe 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 43: Europe Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: Europe Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: Europe 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 46: Europe Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: Europe Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Europe 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 49: France Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: France Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: France 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 52: France Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 53: France Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: France 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 55: Germany Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: Germany Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 57: Germany 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 58: Germany Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: Germany Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 60: Germany 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 61: Italy Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: Italy Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 63: Italy 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 64: Italy Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 65: Italy Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 66: Italy 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 67: UK Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 68: UK Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 69: UK 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 70: UK Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 71: UK Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 72: UK 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 73: Rest of Europe Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 74: Rest of Europe Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 75: Rest of Europe 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 76: Rest of Europe Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 77: Rest of Europe Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 78: Rest of Europe 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 79: Asia-Pacific Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 80: Asia-Pacific Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 81: Asia-Pacific 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 82: Asia-Pacific Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 83: Asia-Pacific Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 84: Asia-Pacific 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027
  • Table 85: Rest of World Current & Future Analysis for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 86: Rest of World Historic Review for High-density Multiplexed Diagnostic Assays by Product - High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 87: Rest of World 15-Year Perspective for High-density Multiplexed Diagnostic Assays by Product - Percentage Breakdown of Value Sales for High-Density Multiplexed Diagnostic Assays (500-10,000 plex) and Very High-Density Multiplexed Diagnostic Assays (>10,000 plex) for the Years 2012, 2020 & 2027
  • Table 88: Rest of World Current & Future Analysis for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 89: Rest of World Historic Review for High-density Multiplexed Diagnostic Assays by End-Use - Clinical Diagnostic Laboratories and Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 90: Rest of World 15-Year Perspective for High-density Multiplexed Diagnostic Assays by End-Use - Percentage Breakdown of Value Sales for Clinical Diagnostic Laboratories and Hospitals and Clinics for the Years 2012, 2020 & 2027

IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown